Home

Propeller Majestätisch Gas ioannis zerdes Vegetation Kommentar Herrin

Ioannis Zerdes (ioanniszerdes) - Profile | Pinterest
Ioannis Zerdes (ioanniszerdes) - Profile | Pinterest

Cancers | Free Full-Text | Discordance of PD-L1 Expression at the Protein  and RNA Levels in Early Breast Cancer
Cancers | Free Full-Text | Discordance of PD-L1 Expression at the Protein and RNA Levels in Early Breast Cancer

PDF) STAT3 Activity Promotes Programmed-Death Ligand 1 Expression and  Suppresses Immune Responses in Breast Cancer
PDF) STAT3 Activity Promotes Programmed-Death Ligand 1 Expression and Suppresses Immune Responses in Breast Cancer

Ioannis Zerdes - Civil Engineer - Self-employed engineering, management &  grant consultant. | LinkedIn
Ioannis Zerdes - Civil Engineer - Self-employed engineering, management & grant consultant. | LinkedIn

Loop | Georgios Georgountzos
Loop | Georgios Georgountzos

Discordance of PD-L1 status between primary and metastatic breast cancer: A  systematic review and meta-analysis - Cancer Treatment Reviews
Discordance of PD-L1 status between primary and metastatic breast cancer: A systematic review and meta-analysis - Cancer Treatment Reviews

Ioannis Zerdes - Glifádha, Attiki, Greece | Professional Profile | LinkedIn
Ioannis Zerdes - Glifádha, Attiki, Greece | Professional Profile | LinkedIn

Ioannis ZERDES | PostDoc / Licensed Physician | MD PhD | Karolinska  Institutet, Solna | KI | Department of Oncology-Pathology
Ioannis ZERDES | PostDoc / Licensed Physician | MD PhD | Karolinska Institutet, Solna | KI | Department of Oncology-Pathology

Ioannis Zerdes - Civil Engineer - Self-employed engineering, management &  grant consultant. | LinkedIn
Ioannis Zerdes - Civil Engineer - Self-employed engineering, management & grant consultant. | LinkedIn

Cancers | Free Full-Text | STAT3 Activity Promotes Programmed-Death Ligand  1 Expression and Suppresses Immune Responses in Breast Cancer
Cancers | Free Full-Text | STAT3 Activity Promotes Programmed-Death Ligand 1 Expression and Suppresses Immune Responses in Breast Cancer

Jonas Bergh's Group | Karolinska Institutet
Jonas Bergh's Group | Karolinska Institutet

Ioannis Zerdes - Civil Engineer - Self-employed engineering, management &  grant consultant. | LinkedIn
Ioannis Zerdes - Civil Engineer - Self-employed engineering, management & grant consultant. | LinkedIn

Ioannis Zerdes - Civil Engineer - Self-employed engineering, management &  grant consultant. | LinkedIn
Ioannis Zerdes - Civil Engineer - Self-employed engineering, management & grant consultant. | LinkedIn

Ioannis ZERDES | PostDoc / Licensed Physician | MD PhD | Karolinska  Institutet, Solna | KI | Department of Oncology-Pathology
Ioannis ZERDES | PostDoc / Licensed Physician | MD PhD | Karolinska Institutet, Solna | KI | Department of Oncology-Pathology

PDF) Plasmablastic Lymphoma with Coexistence of Chronic Lymphocytic  Leukemia in an Immunocompetent Patient: A Case Report and Mini-Review
PDF) Plasmablastic Lymphoma with Coexistence of Chronic Lymphocytic Leukemia in an Immunocompetent Patient: A Case Report and Mini-Review

Ioannis Zerdes - Civil Engineer - Self-employed engineering, management &  grant consultant. | LinkedIn
Ioannis Zerdes - Civil Engineer - Self-employed engineering, management & grant consultant. | LinkedIn

Ioannis ZERDES | PostDoc / Licensed Physician | MD PhD | Karolinska  Institutet, Solna | KI | Department of Oncology-Pathology
Ioannis ZERDES | PostDoc / Licensed Physician | MD PhD | Karolinska Institutet, Solna | KI | Department of Oncology-Pathology

Editorial Board | ARC Journal of Cancer Science | High Impact Journals
Editorial Board | ARC Journal of Cancer Science | High Impact Journals

Zerdes Ioannis Katsiapis Nikolaos in Pireas, Greece Information and Review
Zerdes Ioannis Katsiapis Nikolaos in Pireas, Greece Information and Review

Interplay between copy number alterations and immune profiles in the early  breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial:  results from a feasibility study | npj Breast Cancer
Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study | npj Breast Cancer

Programmed death‐ligand 1 gene expression is a prognostic marker in early  breast cancer and provides additional prognostic value to 21‐gene and  70‐gene signatures in estrogen receptor‐positive disease - Zerdes - 2020 -
Programmed death‐ligand 1 gene expression is a prognostic marker in early breast cancer and provides additional prognostic value to 21‐gene and 70‐gene signatures in estrogen receptor‐positive disease - Zerdes - 2020 -

Ioannis ZERDES | PostDoc / Licensed Physician | MD PhD | Karolinska  Institutet, Solna | KI | Department of Oncology-Pathology
Ioannis ZERDES | PostDoc / Licensed Physician | MD PhD | Karolinska Institutet, Solna | KI | Department of Oncology-Pathology

Ioannis ZERDES | PostDoc / Licensed Physician | MD PhD | Karolinska  Institutet, Solna | KI | Department of Oncology-Pathology
Ioannis ZERDES | PostDoc / Licensed Physician | MD PhD | Karolinska Institutet, Solna | KI | Department of Oncology-Pathology